LIBRETTO-001: selpercatinib in RET fusion-positive non-small-cell lung cancer
The selective RET inhibitor selpercatinib shrank tumours in 64 percent of previously treated and 85 percent of untreated patients with RET fusion-positive lung cancer, including brain metastases, and led to the first approval for this driver.
Overview
Phase 1/2 study of 105 previously treated and 39 treatment-naive patients with RET fusion-positive non-small-cell lung cancer treated with selpercatinib.
Objective response was 64 percent in previously treated patients with median duration of response 17.5 months and median progression-free survival 16.5 months; 85 percent in treatment-naive patients; intracranial response 91 percent among evaluable patients. Hypertension, liver enzyme rise and QT prolongation were the main toxicities.
- Objective response 64 percent (previously treated) and 85 percent (treatment-naive).
- Median progression-free survival 16.5 months in previously treated patients.
RET fusion testing is standard in lung adenocarcinoma and selpercatinib the preferred first-line RET inhibitor, confirmed against chemo-immunotherapy in LIBRETTO-431.
- Single-arm study.
- Hypersensitivity reactions in patients recently treated with immunotherapy.
Similar pages
not linked directly; found by shared links- Key paperLIBRETTO-431: first-line selpercatinib versus chemotherapy with or without pembrolizumab in RET fusion-positive lung cancer
Shares Selpercatinib, RET fusion-positive non-small-cell lung cancer, New England Journal of Medicine.
- TrialA Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
Shares Selpercatinib, RET fusion-positive non-small-cell lung cancer.
- Key paperLIBRETTO-531: selpercatinib versus cabozantinib or vandetanib in advanced RET-mutant medullary thyroid cancer
- TrialA Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRET
Shares Selpercatinib, RET fusion-positive non-small-cell lung cancer.
- TrialLIBRETTO-431
Shares Selpercatinib, RET fusion-positive non-small-cell lung cancer.
- PersonAlexander Drilon
Shares Selpercatinib, RET fusion-positive non-small-cell lung cancer.
- TreatmentPralsetinib
Shares Selpercatinib, RET fusion-positive non-small-cell lung cancer.
- PathwayNon-small cell lung cancer (KEGG map)
Shares Selpercatinib, RET fusion-positive non-small-cell lung cancer.